Chronic Hepatitis B: Preventing, Detecting, and Managing Viral Resistance

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 3, 2008, Pages 268-274

  Keeffe, Emmet B ^a   Dieterich, Douglas T ^b   Pawlotsky, Jean Michel ^c,d   Benhamou, Yves ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d INSERM   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL THERAPY; DISEASE COURSE; GENE MUTATION; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MONOTHERAPY; OFF LABEL DRUG USE; PATIENT CARE; REVIEW; TABLET FORMULATION; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MUTATION; VIRUS REPLICATION;

EID: 40149095458     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.12.043     Document Type: Review

References (66)

1. Centers for Disease Control and Prevention (CDC). Viral hepatitis B. 2006. http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm Accessed: July 17, 2007
2. Glebe D. Recent advances in hepatitis B virus research: a German point of view. World J Gastroenterol 13 (2007) 8-13
3. World Health Organization. Fact sheet no. 204. Hepatitis B. 2000. http://www.who.int/mediacentre/factsheets/fs204/en/ Accessed: July 17, 2007
4. Wasley A., Miller J.T., Finelli L., and Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 56 (2007) 1-24
5. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
6. Arora G., and Keeffe E.B. Chronic hepatitis B with advanced hepatic fibrosis or cirrhosis: impact of antiviral therapy. Rev Gastroenterol Disord 7 (2007) 63-73
7. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 26 (2006) 171-180
8. Bartholomeusz A., and Locarnini S.A. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 26 (2006) 162-170
9. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
10. Andreone P., Gramenzi A., Cursaro C., et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11 (2004) 439-442
11. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 24 Suppl 1 (2004) 3-10
12. Norder H., Courouce A.M., and Magnius L.O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198 (1994) 489-503
13. Beck J., and Nassal M. Hepatitis B virus replication. World J Gastroenterol 13 (2007) 48-64
14. Okamoto H., Imai M., Kametani M., et al. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 57 (1987) 231-236
15. Bartholomeusz A., and Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 78 Suppl 1 (2006) S52-S55
16. Locarnini S., Hatzakis A., Heathcote J., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9 (2004) 679-693
17. Da Silva L.C., Pinho J.R., Sitnik R., et al. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 36 (2001) 476-485
18. Wright T.L. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 24 Suppl 1 (2004) 31-36
19. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
20. Yuen M.F., Kato T., Mizokami M., et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 39 (2003) 850-855
21. Si Ahmed S.N., Tavan D., Pichoud C., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32 (2000) 1078-1088
22. Mutimer D., Pillay D., Shields P., et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 46 (2000) 107-113
23. Zoulim F. Mechanism and viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64 (2004) 1-15
24. Hussain M., and Lok A.S. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat 6 (1999) 183-194
25. Poch O., Sauvaget I., Delarue M., et al. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8 (1989) 3867-3874
26. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27 (1998) 1670-1677
27. Delaney IV W.E., Yang H., Westland C.E., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77 (2003) 11833-11841
28. Fu L., and Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 55 (1998) 1567-1572
29. Seigneres B., Martin P., Werle B., et al. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 47 (2003) 1842-1852
30. Curtis M., Zhu Y., and Borroto-Esoda K. HBV rtI233V polymerase variant remains sensitive to adefovir (abstr). J Hepatol 46 Suppl 1 (2007) S26-S27
31. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
32. Borroto-Esoda K., Arterburn S., Snow A., et al. Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients (abstr). J Hepatol 44 Suppl 2 (2006) S179-S180
33. Langley D.R., Walsh A.W., Baldick C.J., et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 81 (2007) 3992-4001
34. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 44 (2006) 1656-1665
35. Tenney D.J., Rose R.E., Baldick C.J., et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51 (2007) 902-911
36. Colonno R.J., Rose R.E., Pokornowski K., et al. Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients (abstr). J Hepatol 46 Suppl 1 (2007) S294
37. Seifer M., Patty A., Dukhan D., et al. Telbivudine (LdT) preferentially inhibits second (+) strand HBV DNA synthesis (abstr). Gastroenterology 128 Suppl 2 (2005) A742-A743
38. Lai C.L., Gane E., Hsu C.W., et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine (abstr). Hepatology 44 Suppl 1 (2006) 222A
39. Lim S.G., Ng T.M., Kung N., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 (2006) 49-56
40. Yang H., Qi X., Sabogal A., et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10 (2005) 625-633
41. Gish R.G., Trinh H., Leung N., et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 43 (2005) 60-66
42. Delaney IV W.E., Ray A.S., Yang H., et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50 (2006) 2471-2477
43. Lada O., Benhamou Y., Cahour A., et al. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9 (2004) 353-363
44. van Bömmel F., Zollner B., Sarrazin C., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
45. van der Eijk A.A., Hansen B.E., Niesters H.G., et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 12 (2005) 364-372
46. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
47. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
48. Tillmann H.L. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 13 (2007) 125-140
49. Lok A.S., Zoulim F., Locarnini S., et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 40 (2002) 3729-3734
50. Zoulim F. New nucleic acid diagnostic tests in viral hepatitis. Semin Liver Dis 26 (2006) 309-317
51. Tran N., Berne R., Chann R., et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 44 (2006) 2792-2800
52. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. http://AIDSinfo.nih.gov/contentfiles/Adultandadolescent6L.pdf Accessed: July 17, 2007
53. Tang J.W., and Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 30 (2004) 1-10
54. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
55. Peters M.G., Hann H.W.H., Martin P., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
56. Perrillo R., Hann H.W., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
57. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
58. Rapti I., Dimou E., Mitsoula P., et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
59. Lampertico P., Vigano M., Manenti E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
60. Luber A.D. Genetic barriers to resistance and impact on clinical response. EJIAS: eJournal of the International AIDS Society 7 69 (2005) 1-11. http://www.medscape.com/viewarticle/504524_print Available at: http://www.medscape.com/viewarticle/504524_print. Accessed: March 20, 2007
61. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
62. Sung J.J.Y., Lai J.Y., Zeuzem S., et al. A randomised double-blind phase II study of lamivudine (LAM) compared with lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis (abstr). J Hepatol 38 Suppl 2 (2003) 25-26
63. Lau G., Cooksley H., Ribeiro R.M., et al. Randomised, double-blind study comparing adefovir dipivoxil plus emtricitabine combination therapy versus adefovir alone in HBeAg(+) chronic hepatitis B: efficacy and mechanisms of treatment response (abstr). Hepatology 40 Suppl 1 (2004) 272A
64. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
65. Nikolaidis N.L., Giouleme O.I., Tziomalos K.A., et al. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J Gastroenterol Hepatol 20 (2005) 1721-1725
66. Yuen M.F., Wong D.K.H., Fung J., et al. Predictive value of HBV DNA levels at frequent time points during early and maintenance phase of 5-year lamivudine and mutational profiles of reverse transcriptase (RT) and surface (S) genes (abstr). Hepatology 44 (2006) 557A